Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 7, Issue 9, 2012, Pages 1466-1470

  Fennell, Dean A ^a   McDowell, Cliona ^b   Busacca, Sara ^a   Webb, Glen ^c   Moulton, Brian ^c   Cakana, Andrew ^d   O'Byrne, Kenneth J ^e   Meerbeeck, Jan V ^f   Donnellan, Paul ^g   McCaffrey, John ^h   Baas, Paul ⁱ  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c All Ireland Cooperative Oncology Research Group   (Ireland)

^d JOHNSON AND JOHNSON   (United States)

^e ST JAMES S HOSPITAL   (Ireland)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY HOSPITAL GALWAY   (Ireland)

^h MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Bortezomib; Chemotherapy; First line; Mesothelioma; Second line

Indexed keywords

BORTEZOMIB; PROTEIN BCL 2; PROTEIN NOXA;

AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84865697291     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318260dfb9     Document Type: Article

References (15)

1. Robinson BW Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603. (Pubitemid 41434638)
2. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-147.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. (Pubitemid 46606305)
4. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4:97-101.
5. Giaccone G, O'Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002;38 Suppl 8:S19-S24. (Pubitemid 41127956)
6. Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008;27:1189-1197. (Pubitemid 351294694)
7. Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007;13:5942-5951. (Pubitemid 47583922)
8. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008;61:549-558.
9. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-2121. (Pubitemid 41095144)
10. Jansson AK, Emterling AM, Arbman G, Sun XF. Noxa in colorectal cancer: a study on DNA, mRNA and protein expression. Oncogene 2003;22:4675-4678. (Pubitemid 36976442)
11. Byrne MJ Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
12. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells. Mol Cancer 2010;9:110.
13. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
14. Chen S, Blank JL, Peters T, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 2010;70:4318-4326.
15. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 2008;7:50.